Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 4, 2007, Pages 411-416

  Hartzell, Joshua D ^a,b   Spooner, Katherine ^a,c   Howard, Robin ^a   Wegner, Scott ^c   Wortmann, Glenn ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c Tri Service AIDS Clinical Consortium   (United States)

Author keywords

Highly active antiretroviral therapy; HIV; Race; Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK; RISK FACTOR; TREATMENT FAILURE; VIRUS LOAD;

ADULT; AFRICAN AMERICANS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL HEALTH; MILITARY MEDICINE; MILITARY PERSONNEL; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 34147100621     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31802f83a6     Document Type: Article

References (39)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigation. JAMA. 1998;280:1497-1503.
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
4. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
5. Stern JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-384.
6. Mellors J, Munoz A, Giorgi J, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
7. Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active retroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
8. Lucas G, Chaisson R, Moore R. Survival in an urban HIV-1 clinic in the era of HAART: a 5-year cohort study. J Acquir Immune Defic Syndr. 2002;33:321-328.
9. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective study. Lancet. 1999;353:863-868.
10. Deeks S, Hecht F, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13(Suppl):F35-F43.
11. Enanoria W, Ng C, Saha S, et al. Treatment outcomes after highly active antiretroviral therapy: a meta-analysis of randomized controlled trials. Lancet Infect Dis. 2004;4:414-425.
12. Lucas GM, Weidle PJ, Hader S, et al. Directly administered antiretroviral therapy in an urban methadone clinic: a nonrandomized comparative study. Clin Infect Dis. 2004;38(Suppl):S409-S413.
13. Moore R, Keruly J, Gebo K, et al. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr. 2005;39:195-198.
14. Anastos K, Gange SJ, Lau B, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr. 2000;24:218-226.
15. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med. 2000;160:1123-1132.
16. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. EuroSIDA Study Group. J Infect Dis. 2001;183:1290-1294.
17. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15:1115-1123.
18. Simoni JM, Frick PA, Pantalone DW, et al. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med. 2003;11:185-198.
19. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2004. Vol. 16. Atlanta, GA: US Department of Health and Human Services, CDC; 2005:1-46.
20. Yamashita TE, Phair JP, Munoz A, et al. An immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS. 2001;15:735-746.
21. Jensen-Fangel S, Pedersen L, Pedersen C. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002;35:1541-1548.
22. McGinnis KA, Fine MJ, Sharma RK, et al. Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health. 2003;93:1728-1733.
23. Anastos K, Schneider M, Gange S, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537-544.
24. Silverberg MJ, Wegner SA, Milazzo MJ, et al. Effectiveness of highlyactive antiretroviral therapy by race/ethnicity. AIDS. 2006;20:1531-1538.
25. Ribaudo H, Clifford D, Gulick R, et al. Relationships between efavirenz pharmacokinetics, side-effects, drug discontinuation, virologic response, and race: results from ACTGA5095/A5097s [abstract 132]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco.
26. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir. Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003;47:130-137.
27. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-721.
28. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health. 2004;94:1133-1140.
29. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1466-1474.
30. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394-402.
31. Turner BJ, Laine C, Cosler L, et al. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18:248-257.
32. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S136-S139.
33. Prins M, Meyer L, Hessol N. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS. 2005;19:357-370.
34. Nicastri E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS. 2005;19:577-583.
35. Farzadegan H, Hoover D, Astemborski J. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998;352:1510-1514.
36. Giordano T, Wright J, Hasan M, et al. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis. 2003;37:433-437.
37. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active retroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004;18:2029-2038.
38. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-2444.
39. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006;57:4-7.